How to buy Cara Therapeutics shares

Own Cara Therapeutics shares in just a few minutes.

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Cara Therapeutics, Inc is a biotechnology business with stocks listed in the US. Cara Therapeutics shares (CARA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$13 – a decrease of 4.34% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in Cara Therapeutics

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Cara Therapeutics. Find the share by name or ticker symbol: CARA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cara Therapeutics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$13, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Cara Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Cara Therapeutics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Cara Therapeutics share price

Use our graph to track the performance of CARA stocks over time.

Cara Therapeutics shares at a glance

Information last updated 2021-06-17.
52-week rangeUS$11.8 - US$29.6473
50-day moving average US$13.6891
200-day moving average US$18.0455
Target priceUS$27.63
PE ratio 50.5172
Dividend yield N/A (0%)
Earnings per share (TTM) US$0.29

Compare share trading platforms to buy stock

Name Product Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro (US, EU stock trading)
US$0
US$10 per month if there’s been no login for 12 months
0.50%
Global shares, US shares, ETFs
Zero brokerage share trading on US stocks with trades as low as $50.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
US$0
$50 per quarter if you make fewer than three trades in that period
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Saxo Capital Markets (Classic account)
US$9.9
No
0.75%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Acess 19,000+ stocks on 37 exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Stockbroking
US$0
No
0.60%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Cara Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Cara Therapeutics price performance over time

Historical closes compared with the last close of $13

1 week (2021-06-11) -6.88%
1 month (2021-05-21) -2.03%
3 months (2021-03-19) -33.77%
6 months (2020-12-18) -13.91%
1 year (2020-06-19) -21.78%
2 years (2019-06-20) -35.87%
3 years (2018-06-20) -21.88%
5 years (2016-06-20) 152.92%

Is Cara Therapeutics under- or over-valued?

Valuing Cara Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cara Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Cara Therapeutics's P/E ratio

Cara Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 51x. In other words, Cara Therapeutics shares trade at around 51x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Cara Therapeutics's EBITDA

Cara Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$12 million.

The EBITDA is a measure of a Cara Therapeutics's overall financial performance and is widely used to measure a its profitability.

Cara Therapeutics financials

Revenue TTM US$128.9 million
Operating margin TTM 9.17%
Gross profit TTM US$27.2 million
Return on assets TTM 3.31%
Return on equity TTM 7.18%
Profit margin 10.88%
Book value 4.607
Market capitalisation US$733.3 million

TTM: trailing 12 months

Shorting Cara Therapeutics shares

There are currently 3.1 million Cara Therapeutics shares held short by investors – that's known as Cara Therapeutics's "short interest". This figure is 11.9% down from 3.6 million last month.

There are a few different ways that this level of interest in shorting Cara Therapeutics shares can be evaluated.

Cara Therapeutics's "short interest ratio" (SIR)

Cara Therapeutics's "short interest ratio" (SIR) is the quantity of Cara Therapeutics shares currently shorted divided by the average quantity of Cara Therapeutics shares traded daily (recently around 1.5 million). Cara Therapeutics's SIR currently stands at 2.16. In other words for every 100,000 Cara Therapeutics shares traded daily on the market, roughly 2160 shares are currently held short.

However Cara Therapeutics's short interest can also be evaluated against the total number of Cara Therapeutics shares, or, against the total number of tradable Cara Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cara Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Cara Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0745% of the tradable shares (for every 100,000 tradable Cara Therapeutics shares, roughly 75 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cara Therapeutics.

Find out more about how you can short Cara Therapeutics stock.

Cara Therapeutics share dividends

We're not expecting Cara Therapeutics to pay a dividend over the next 12 months.

Have Cara Therapeutics's shares ever split?

Cara Therapeutics's shares were split on a 1:2 basis on 15 January 2014. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cara Therapeutics shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for Cara Therapeutics shares which in turn could have impacted Cara Therapeutics's share price.

Cara Therapeutics share price volatility

Over the last 12 months, Cara Therapeutics's shares have ranged in value from as little as US$11.8 up to US$29.6473. A popular way to gauge a stock's volatility is its "beta".

CARA.US volatility(beta: 1.13)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cara Therapeutics's is 1.1293. This would suggest that Cara Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Cara Therapeutics overview

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site
Not sure what platform to go with?
Take this quick quiz to find the right share trading platform